MARLBOROUGH, Mass., May 11, 2015 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced that key data from 42 abstracts will be featured at the 36th Annual Scientific Sessions of the Heart Rhythm Society (HRS) in Boston on May 13-16.
Following recent successes – including the U.S. Food and Drug Administration (FDA) approvals of the WATCHMAN™ Left Atrial Appendage Closure Device and the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System, as well as the commercial roll-out of the EMBLEM S-ICD System in Europe and of the Rhythmia™ Mapping System in the United States – the company's planned data presentations at HRS will underscore:
- The long-term safety and efficacy of the industry's only Subcutaneous Implantable Defibrillator (S-ICD);
- Multiple sources of device longevity data proving the industry-leading performance of the EnduraLife™ Battery Technology in Boston Scientific defibrillators, as well data highlighting premature replacement procedures due to early battery depletion of devices without this battery technology
- The beneficial economic impact the WATCHMAN Device is projected to have on Medicare in comparison to warfarin and aspirin for stroke risk reduction in indicated patients with non-valvular atrial fibrillation;
- The quality of the mapping data obtained in the initial human experiences using the high-resolution Rhythmia Mapping System to guide cardiac ablation procedures.
"The data presented at this meeting add substantially to the mounting evidence, experience and successes physicians are seeing with these novel therapies," said Kenneth Stein, M.D., chief medical officer, Rhythm Management, Boston Scientific. "We are pleased to continue delivering on our commitment to help improve the care of patients with cardiac rhythm disorders."
ABSTRACTS OF INTEREST (listed chronologically within product categories)
Subcutaneous Implantable Defibrillator (S-ICD) Data Presentations
- Outcomes in Patients with Congenital Heart Disease receiving the Subcutaneous Implantable Defibrillator (S-ICD): Results from a Pooled Analysis from the IDE Study and EFFORTLESS Registry (PO02-204): Benjamin A. D'Souza will present on Thursday, May 14 at 9:30 AM in the EPicenter Exhibit Hall.
- The Patient Perspective on the entirely Subcutaneous Implantable Defibrillator System: Early Results from the EFFORTLESS S-ICD Quality of Life Substudy (PO03-61): Susanne S. Pedersen will present on Thursday, May 14 at 2:00 PM in the EPicenter Exhibit Hall.
- Performance of the Subcutaneous Implantable Cardioverter Defibrillator in Primary Prevention Patients (AB28-02): Lucas V. A. Boersma will present on Friday, May 15 from 1:45 - 2:00 PM in Ballroom East.
- Learning Curve associated with Implantation of the totally Subcutaneous Implantable Defibrillator: Results from a Pooled Analysis of 882 Patients from the IDE Study and EFFORTLESS Registry (AB26-04): Tom F. Brouwer and Reinoud E. Knops will present on Friday, May 15 from 2:15 - 2:30 PM in Room 210B.
Cardiac Resynchronization Therapy Defibrillator (CRT-D) and Implantable Defibrillator (ICD) Data Presentations
- Device Longevity in a Contemporary Cohort of ICD/CRT-D Patients undergoing Device Replacement (PO02-40): Francesco Zanon will present on Thursday, May 14 at 9:30 AM in the EPicenter Exhibit Hall.
- Large Capacity LiMnO2 Batteries extended CRT-D Longevity in Clinical Use Compared to Smaller Capacity LiSVO Batteries Over 6 Years (PO04-42): Ernest Lau will present on Friday, May 15 at 9:30 AM in the EPicenter Exhibit Hall.
- Patient Activity following Implantable Cardioverter-Defibrillator Implantation: The ALTITUDE Activity Study (AB27-01): Daniel Kramer will present on Friday, May 15 from 1:30 - 1:45 PM in Room 210C.
- Projected Number of Replacements Required During Natural Lifespan of CRT-D/ICD Recipients by Age at First Implantation for Different Device Longevity (PO06-26): Ernest Lau will present on Saturday, May 16 at 9:30 AM in the Grand Ballroom Foyer, Level 3.
- Comparison of Advisory and Non-Advisory ICD Leads Using a Novel Lead Alert (PO06-38): Brian Powell will present on Saturday, May 16 at 9:30 a.m. in the EPicenter Exhibit Hall.
WATCHMAN Device Data Presentations
- Medicare Budget Implications of Three Stroke Risk Reduction Strategies in Non-valvular Atrial Fibrillation: Left Atrial Appendage Closure versus Warfarin versus Aspirin (PO01-41): Ken Stein and Stacey Amorosi will present at 6 p.m. on Wednesday, May 13 in the EPicenter Exhibit Hall.
Electrophysiology Data Presentations
- Rhythmia Mapping System: Feasibility, Safety and Short-Term Efficacy in Left Atrial Procedures: The Initial Multicenter Experience in the U.S. (PO03-89): Elad Anter will present on Thursday, May 14 at 2:00 p.m.
- The Use of a New Rapid High-Resolution Mapping System to Assess Conduction Block and Precise Location of Gaps on Linear Lesions - Initial Experience in Human (AB32-01): Lilian Mantziari and Tom Wong will present on Friday, May 15 from 1:30-1:45 PM in Room 254A.
All programs are listed in Eastern Time and will take place at the Boston Convention & Exhibition Center unless otherwise noted. For more information, visit Boston Scientific at booth #929.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, our products, data presentations and impact of data. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.
Boston Scientific Corporation
Susie Lisa, CFA
Boston Scientific Corporation
(508) 683-5565 (office)
SOURCE Boston Scientific Corporation